Entacingene turiparvovec

N/A

Report date: 2025/07/01 15:17:20

Base Information

Drug NameEntacingene turiparvovec
Drug Alias NameAAV2/8-hCARp.hCNGB3AAV-CNGB3Adenovirus associated viral vector serotype 8 containing the human CNGB3 geneA-002
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV8 vector
Mechanisms of ActionGene transferenceCyclic nucleotide-gated cation channel beta-3 stimulants
TargetsCyclic nucleotide-gated cation channel beta-3
Therapy Area/IndicationsColor Vision Defects
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMeiragtx Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMeiragtx Uk Ii Ltd
Active IndicationsN/A
Inactive IndicationsColor Vision Defects

Other Information

ATC CodeN/A
Related LinksN/A